Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Thank you. And again, welcome to the Devyser Q3 2024 Earnings Call. It's a real pleasure to have you all here. Today, you will be listening to me. Fredrik Alpsten, the Devyser CEO, and Theis Kipling, our Chief Commercial Officer, are responsible for business development. I have also asked our CFO, Sabina Berlin, to join us during the Q&A session. It's very gratifying to see the impact we are having in the field of diagnostics at the moment. We have just returned from the ASHI event, a major conference in the US, and it's clear that many things are going our way at the moment. This applies not only to transportation but also to our other areas of operation. Several milestones were reached during the quarter. We moved all our production and development to our new, proud premises. A number of product registrations were granted around the world. Product development is continuing unabated. The positive signals that we are seeing mean that we invested significantly more during the quarter and the period than last year. Today we embark on a journey through our Q3 results. The second part of the presentation will be dedicated to the highlights, key achievements from the quarter, and we will also discuss the commercial outlook. Organic growth for the quarter was low. Revenue amounted to 48.7 million, which is an organic growth compared to the same quarter of last year of 4% in USD and 7% in local currency. This is lower than we would have liked. But as we have explained, I think, in more or less all our quarterly presentations during the recent years. The figures for some individual quarters may be better or worse than others. The most important thing is that we are expecting the strong growth trend that we have seen in recent years to continue. I would also like to comment. Q3 is considered a holiday quarter for Southern Europe. And as you know, we have significant sales in the southern part of Europe. However, last year we suddenly had the best quarter ever during Q3. And that's one reason: the inventory built up by Thermo Fisher during that quarter. With our innovative products, high market growth, a well-suited commercial organization that we have heavily invested in over the last quarters, and some of the best commercial partners, we are confident that the positive sales trend we have seen in recent years will not only continue but also strengthen. I said we may face individual quarters that do not perform as well, but the overall trend is crystal clear. Our sales are still on a significant upward trajectory, with most quarters expected to be record-breaking. During the quarter, we performed well in our direct markets in Europe and we can see continued opportunities to grow even further here. Our performance in our distributed markets in Europe, the Middle East, Africa, and Asia remains strong. The collaboration with Thermo Fisher is developing very well, and we are very satisfied with it. The low sales during the quarter should not be interpreted as a reduced commitment on our part, but rather as irregular purchasing patterns. We see a continued strong focus from Thermo Fisher on our products and our collaboration. Europe grew by 27% compared with the previous 12 months. Asia Pacific grew by 43% compared with the previous 12 months. During the last 12 to 18 months, we have signed up quite a few new distributors in Asia, and some of them have now started to generate revenue. The sales in North and South America were low compared with last year. However, we are very optimistic about North America and are currently investing heavily in this market. The potential in North America is massive, and we have just started to penetrate this market. North America will be one of our top priorities for the near, mid, and long term. Our direct sales represented about 75%, and our distributor sales represented 25% of total revenue for the quarter and for the last 12 months. However, as sales through Thermo Fisher Scientific are increasing and new distributors in regions like Asia and the Middle East are added, we may see an increased distributor share of revenue going forward. Talking about Thermo Fisher, I'm glad to report today also that we in October achieved our best quarter ever and that will be reported as revenue in Q4. One of Devyser's strengths is its business model. We have very high gross margins because we sell only consumables and software, not equipment. Over the last few years, we have increased the gross margin from around 75% to about 80%. The reason is a scalable production process and our ability to increase prices, as previously communicated, we decided in spring 2023 to move to a bigger facility to enable higher product volumes and automate the production processes. The move to our new facility has taken place mainly during the second and third quarters of 2024. We have worked extensively to build up the production and R&D parts of the facility. As with all certified and regulated industries, this must be done by the book, documented, validated, and verified. It must be approved by the regulatory authorities and notified bodies when ready. Everything is now ready, and we will have the inauguration of the new facility on November 6th. All work to finalize the new facility has been costly. Cost was negatively impacted in both the second and third quarters. That's the reason why the gross margin has decreased from 85% to 72%. The investment in our new facility will help us to drive down production costs in the future, even further, and help us continue automating the production processes and accordingly increase our gross margins over the long run. It should also be mentioned that to minimize risk, we decided to rent both facilities, both the old one and the new one, during the full year of 2024. This means that we go into 2025. We will not pay rent for the old facility. The quarter's EBIT was more or less in line with our expectations. It amounted to -24,000,006 compared with -8 million. Same quarter last year. The lower result is, among other things, caused by costs associated with the move to the new premises. The lower result can also be derived from increased costs for our expansion in North America and costs for incentive programs resulting from the favorable share price development. However, we are not completely satisfied with the overall expense development. As a rapidly growing company, it's sometimes difficult to maintain. Maintain total cost control to speed up the route to profitability. We have reviewed the cost base in the company during the third quarter and carried out some organizational changes. Costs for this have been charged to the quarter's result. We are convinced that the positive earnings development that we saw in 2023 will continue, and that we will reach our financial goal of an EBIT margin exceeding 20%, sometime between 2024 and 2026. Devyser has a very strong financial position, with 171 million in cash at the end of the quarter and no interest-bearing debts. With that, I'll turn it over to Theis Kipling.
Thank you. Fredrik. Q3 was another quarter with a lot of progress across the organization and especially within the US, which I have been looking forward to sharing with you today. Devyser attended the annual AG meeting last week, which is a pivotal event within the transplantation field. This was our third time attending the event, and beyond the many data presentations featuring our products. It was great to hear from customers, and not least to see how Devyser's transplantation products are now a cornerstone of Thermo Fisher Scientific's transplantation business. We had an impressive number of posters and scientific presentations featuring our products, and we're now starting to see large institutions publish their own independent research. One highlight was a study done by the University Hospital of Copenhagen, which compared the performance of Devyser and CareDx NGS-based assays for monitoring donor-derived cell-free DNA in kidney allograft patients, which, amongst other things, concluded that the Devyser kit has a slightly lower limit of detection and overall is a robust assay on par with the established KD Rd assays for monitoring donor-derived cell-free DNA as an adjunct biomarker in organ transplant patients, and concluded that our product is non-inferior compared to the current market standard. I can tell you it is not to be underestimated. Beyond our currently available products, we also presented posters, including some new product launches within transplantation planned to come out during 2025, and we expect these products will significantly boost our growth and also cement our position as a clear leader within the transplantation field. This week, you may have seen that we have announced a very instrumental agreement with Thermo Fisher, as we now will team up to bring our solid organ monitoring test through for FDA approval and hence Devyser will benefit from Thermo's highly successful track record of working with the FDA. We will collaborate on the preclinical and clinical data developments and share the associated costs. We initially will pursue the kidney indication, but this has the potential to expand across multiple indications over the years. This is probably one of the most important agreements made in the history of our company, as it enables this alliance between Devyser and Thermo Fisher Scientific to disrupt the current market. In the US, hundreds of millions of dollars are spent every year just on post-transplantation monitoring, led by a few testing service providers, simply due to the fact that there is no FDA-approved product available for post-transplantation monitoring of solid organs. The vision behind developing the Devyser transplantation products is to democratize testing, which will shorten turnaround times and lower the general expenses to society related to running these tests compared to today's standard, enabling hospitals to bring back testing into their own laboratories. It not only improves turnaround times but also enables hospitals to benefit from significant revenue streams that today are sent out to external companies. We believe that this approach is the recipe for long-term revenue success for us in the United States, and will become a leading revenue driver for Devyser. While it will take some years before we can realistically obtain FDA approval, we have worked diligently on finalizing the validation process for our Solid Organ Transplantation test in our US CLIA-certified laboratory, including preparing for reimbursement in accordance with our go-to-market strategy. We anticipate obtaining reimbursement between Q2 and Q3 of 2025, and will provide more guidance on how we will commercialize the product during our Capital Markets Day planned for November. We are gradually increasing our test menu in the lab while expanding our commercial engagements, which came a long way during Q3 of this year. The past months, I can tell you, have been hectic but exciting, as several very large US companies have noticed that Devyser is now open for business in the US, and thus I expect that I can share news about new large wins during the months ahead of us. Our fastest growing products globally, beyond our traditional products, are our tests for cystic fibrosis and thalassemia, which are all poised for success in the US. We are on track to secure reimbursement for RHD tests in the lab, and will continue our work to secure reimbursement for all these products. RHD continues to take market share beyond Hema-Quebec in Canada, which we have previously announced. We are now also working with Canadian Blood Services and hence have a solid future growth platform in Canada. Once these accounts are expected to reach clinical routine testing during the second half of 2025. I have always been bullish about the potential that our RHD test also has in the US, which remains unchanged. During Q3, we made significant headway in commercialization within the US, and I'm confident that RHD will be one of our best-selling products in the US. We do see consistent demand and potential for both our cystic fibrosis and thalassemia tests within the US, and we are actively pursuing a number of opportunities, including securing regulatory access and reimbursement with the IBD agreements signed together with Illumina during Q3. We now have a pathway also towards getting these products through for FDA approval, which we will be guiding on in more detail later on. On Monday this week, we received the good news about the regulatory approval of Devyser Compacts in China, which has been a very long process together with our local distributor in China. We have now taken a lot of learnings with us that we will be using to gain an increased number of product approvals in China, which is a great market, as you all know, and equally represents a significant opportunity for Devyser due to the market's complexity, the language barriers, and so forth. Up until now, we have been cautious and have not focused much on China. However, on the back of this approval, we are accelerating our focus here, including hiring additional staff to help the distributor in China penetrate the market while getting more products approved. While today has been focused on our growth developments primarily in North America, I'm happy to share that business is following plan in all our territories, with the exception, as Fredrik mentioned, regarding the phasing of Thermo Fisher orders. We continue to add more talent to our European business in response to the consistent growth we are seeing in several of these markets, excluding Italy. We've had only one employee on the ground, but today we have 3 to 4 salespersons knocking on doors with customers and growing fast in alignment with our revenue expansion in these markets. We continue to also see double-digit growth in Italy across our product portfolio and even within segments where we are already the clear market leader across the other large European markets. We expand our market share and post high double-digit growth on a year-to-date basis. Lastly, we covered a lot of ground during Q3, which positions us well for Q4. As already alluded to for 2025, I'm excited about the potential that we have and to be sharing the wins as they come in during the coming months ahead of us. And with that, Fredrik, I'll pass it back to you.
Thank you.
Guys. As you know, over the last two years we have taken some very important steps to build a global, fast-growing, highly profitable diagnostic company. As you have also heard, we are optimistic about the future with our innovative products, high market growth, a well-suited commercial organization that we have heavily invested in over the last quarters, and some of the best commercial partners. We are confident that the historical development we have observed can continue and even improve. However, as important as high growth is, continuing our way to profitability remains our main focus. As announced last week, we will, for the first time ever, have a Capital Market Day on November 25, 2025. See our homepage for more information and welcome to that day. With that, I open up for questions. Cleve, over to the operator.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Ludvig Lundgren from Nordea. Please go ahead.
Hi, Fredrik and Theis. Um, a few questions from my side. First of all, you mentioned here that you had received the largest order ever from One Lambda. If I heard you correctly, would it be possible to quantify this or at least quantify the historical order values from them?
Uh, no. We respect our collaboration with Thermo Fisher Scientific, and we cannot disclose.
Uh.
Numbers. Sorry for that.
Um. No worries. But then maybe on visibility in the distributor channel. How would you say this typically is, do you know in advance of an order looking into Q4 and potentially into 2025 how this will develop moving forward?
Maybe it's a question for you guys. Um.
Yeah, absolutely. And just to clarify, do you refer to distributors including Thermo Fisher, or are you excluding them?
Yeah. I was thinking specifically about Thermo Fisher Scientific. Yeah.
No, we have, um, you know, with Thermo Fisher, as we're building up a market, it will be a little bit lumpy, right? As we are seeing. So, we have, as they are, a building inventory on their side. That means it will be lumpy, and you should expect it to continue being so. That said, I expected it, but I'm very pleased we are now receiving the largest order ever from Thermo Fisher and One Lambda, right? Um, and that is a trend that will continue. But you should expect it to be lumpy, month to month, quarter to quarter as they build stock and sell more. Until we get a few years in, we won't see easily projectable revenue streams in this respect; however, we anticipate rapid growth. I hope that answers your question.
And maybe I can add that they also have channel partners. So they also have irregular sales from them. They have their direct organization in Europe, and especially in the US. But outside there, they have us working with the channel partners.
Got it. Then, perhaps on the topic of gross margins. You stated here that it was negatively affected by the move to new premises. Could you quantify the moving costs in Q3 and also looking ahead, if you expect any further costs related to this in Q4?
No.
We are very careful about giving forecasts, but we are confident that we will soon be back to about 80% of our financial targets. Maybe we can stay with that.
Okay, great. And then, the final one just here on yesterday's news with the One Lambda collaboration on the FDA approval; could you maybe walk us through the timeline? And also, can we expect an approval already in late '25, or is this more a '26 event?
We have not yet decided. Communicate the timeline. We would like to have progressed further before we disclose that. My experience is that if you do get a delay, it can be problematic. So, we would like to be firm about the timeline before we communicate it. So. So we will be a bit hesitant. For the time being, I don't think we will communicate anything this year. We will communicate the earliest beginning next year about the timeline.
Okay. And with this new collaboration, will it come with additional costs compared to what you previously expected?
No, it's actually the opposite. Now, we don't need to take on all the costs ourselves. We will share the cost.
Okay. Thank you. I'll get back into the queue.
Thank you, thank you.
The next question comes from Ulrich Trattner of Carnegie. Please go ahead.
Thank you very much. And good morning. I have a ton of questions, so I'll just fire them off. Um, again, if you can talk a bit about, well, first of all, you sound extremely optimistic about this Canadian blood service beyond what's already been awarded in your tenders. Could you provide more details on your optimism regarding the expansion of RHD testing in Canada, and what that might entail in terms of volumes compared to the contracts you have already secured?
I can take that question further. Yeah, yeah, yeah, yeah. You're right. I mean, between Hema-Quebec and Canadian Blood Services, we should be able to cover most of the nation of Canada and their RHD testing. And I will be a little hesitant giving you more firm guidance because we are waiting. There's a pretty large tender that has yet to be clarified in their largest region, Ontario. And the latest news we have is that it will be confirmed by late November; it has already been delayed and should have been communicated by late October. So, that will indeed change the outlook. Um, so I'll keep the forward-looking guidance to myself for the time being. But you know, I'm very optimistic. Between Hema-Quebec and Canadian Blood Services, we will have most of the market in Canada. And I think that is a fantastic position beyond other nations where we are the clear market leader for RHD screening, also in Europe. As I mentioned, that's part of why I remain bullish about the potential in the US.
And just a follow-up, are you still offering the product for RHD screening in Canada that meets the mandatory requirements of tenders, and remains the only product validated by Blood Canada?
That's the intelligence that we have, at least.
Okay, great. Um, then a follow-up on the phasing of revenues in Q4. You have been awarded large tenders in Italy. Record tender on your end. The awarded tender for RHD screening in Canada remains to be delivered based on the Cyted agreements. And then, of course, you talked about the largest order ever from One Lambda into Q4. So how should we think about phasing of revenues? Obviously, you had a stellar Q2. Now we're looking at a soft Q3, but how should we view phasing into Q4?
Yes, we are a bit hesitant to give guidance. We are, of course, more positive about Q4 than we were about Q3. If that helps. If I were to.
Raise my question, then. Yeah, sure. Fredrik. And if I were to rephrase my question, going back to the previous comments on your end, were you expecting to see H2 showing acceleration in growth versus H2 of last year? Um, now having seen weak Q3, does that sort of comment still stand that you were expecting to see growth acceleration in the second half of the year?
Uh, yeah. We have not changed our outlook. I didn't follow you. I didn't follow what you said. But what we said earlier remains.
Okay, great.
Which indicates a positive outlook, suggesting a strong Q4 because Q3 was poor.
Yeah, maybe I can just add a supporting comment. Uh, Ulrich, I mean, um, the good thing with Devyser is that we honestly don't lose customers. Uh, and it's so that all the customers we had last year, we have today and then some. So that's why, you know, as Fredrik mentioned in the Q2 call, we firmly believe that H2 will continue that strong growth. We have also posted in H1, so that you're not overlooking Q3. And I think that should answer what we are also aiming to be posting for Q4 and beyond.
But could you give some clarification?
On delivery of the Cyted agreement for Q4, as well as the RHD tender that has already been awarded on your end and validated, will that have had an impact on Q3, and how should we view that going into Q4?
Yeah, let's start with the Cyted agreement in the lab. So there we had lots of traction in Q2, less in Q3, expecting that to go back in Q4 and also expecting that I will be coming out with more updates and news on that whole collaboration. Um, so, that's absolutely still there, doing well. Uh, Hema-Québec. As we have mentioned during the Q2 call and previously, that has been delayed. Right. And we are expecting that to really kick off during the second half of 2025. As I also mentioned during my update today.
Uh, and it's so that all the customers we had last year, we have today and then some. Um, great. And strategically here, you talk about a lot of focus, both near-term, mid-term, and long-term, on expanding your commercial operations in the US. And I just want to get your mindset on where we're moving, given yesterday's news about your aim to obtain FDA approval for the kidney monitoring kits. And as you mentioned on the call. And then I think it's fair to assume that you would pursue that for your RHD and Cystic Fibrosis tests as well. But once you enter into the FDA-approved space, you're going against a very large market, like all hospitals, or generalized labs. Would that in turn position you more towards going for a distribution partner rather than going yourself? And I guess this overall would increase your attractiveness to find a big distribution partner versus previously.
You can take that advice.
Yeah. I mean, let's start with what we have done with Thermo Fisher. I think that, um, I can only encourage you obviously to attend some of these conferences within the transplantation field. And, had you been there a couple of years back, you would have noticed that we are absolutely known by everybody now. And that's due to the partnership with Thermo Fisher, which has accelerated the penetration much beyond what we could have done ourselves and at a much lower cost. So I think that that is a proven success model for Devyser, whether that's going to be the same model we will pursue for Cystic Fibrosis or RHD. I will remain unanswered for the time being. I think you will see more guidance on that. But, um, I will leave you with the conclusion that we are really happy with what we're doing together with Fisher in the transportation space. And I think that is a confirmation of how we as a company are commercializing and implementing the strategy behind.
Okay, great.
And just on the news coming out of ASHI, I read a few application notes published by One Lambda and Thermo Fisher on both upstream and downstream workflows on DNA extraction, as well as results on different types of sequencers. How important are these application notes? I know that they provided examples from Tianjin and Promega, and I guess that would help achieve higher penetration or user rates compared to not having these applications. I would suggest just sort of your take on how important this is.
Yes, absolutely. You're correct in that conclusion; that's exactly, you know, the essence of what they are also trying to convey on their behalf. But what I am pleased to see is that they are actually lowering the barriers to adopting Thermo Fisher as a provider. And so they think holistically end-to-end throughout the workflow, you know, both pre and post transplantation, including that in the workflow. So from my side, I can only salute what they're doing.
Yeah. Great. Uh, and last question on my end, and I'll get back into the queue and stop bothering you guys. Regarding FDA approval, this significantly ties into your recent collaboration with Illumina, given that MiSeq is the only FDA-approved sequencer on the market today. Uh, just how does that play into creating a barrier of entry as well as since you mentioned going into potentially approving Cystic Fibrosis? In my view, or at least from what I know, one of the main competitors to your test kit for cystic fibrosis is a test kit from Illumina. So, how would this complicate things?
It could, or it might not. Let's come back to that later. I can leave you with the teaser that whenever we are up against Illumina in a head-to-head, I usually come back with an order.
Okay.
Um, I'll have to leave you with that concluding remark, then. Thank you, Fredrik.
And thank you, Ulrik.
The next question comes from Philip Wiberg from Pareto Securities. Please go ahead.
Hi. I've got two additional questions. Most of them have been answered. But. But just one on, uh. What makes you so confident in returning to the growth trend we've seen in the past? So you mentioned that you had the Thermo Fisher order now in Q4. Um, but my question is then, if you have seen any positive indicators in southern Europe now post the holidays as well, or for that reason in other regions in Europe, that makes you confident that those geographies will perform well. Um, in addition to this Thermo Fisher Scientific order.
Or maybe you could answer that.
Yes.
I mean, I'm full of confidence that, you know, we are. As I said, if you exclude this lumpiness in building up the market with Thermo Fisher, year to date, we're on track across the channels. I have no reason to believe that there should be any change.
Okay. But if you then look at Southern Europe as well. Um, have you seen any positive indicators now post the holidays in those regions?
Yeah. I mean, especially our largest market, Italy. Right. That's usually the leading indicator that I refer to when I want to see how the business is overall tracking. And those guys are still on fire. They're doing fantastic. They performed well in Q3, having closed additional tenders. And, you know, the Q2, who? I'd say the success that we also communicated. Uh, will. Now it takes some time before it really kicks in. And those tenders are coming into full effect. And I think the more we get into Q4 and Q1 of next year, the more we will see that increased traction in Italy. And that is a leading indicator of how the general market in our large European territories is also developing.
Yeah. Okay. Thanks. And the other question I had was on the gross margin, and you did not want to answer any specifics regarding the breakdown of this extra cost related to the move to new premises. But if I could phrase the question like this, I suppose that the gross margin would have been about this 80% target that you have. If without these additional costs, would that be fair to assume?
That's correct.
Yeah.
Okay. Yeah. That's all for me. Thanks a lot.
Lot.
Thank you.
As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
Thank you for calling in and listening to our earnings call. Please be aware that we have a Capital Market Day on November 25th. So if you are interested in participating, go to our homepage and send us a message about that. So with that. Thank you. Bye bye.



















